Teva Among Beneficiaries As Bystolic Antitrust Case Dismissed
Agreements In 2012 And 2013 Alleged To Have Delayed Competition Until 2021
Executive Summary
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.
You may also be interested in...
ANI Ready For Full-Scale Commercial Launch Of FDA-Approved Cortrophin Gel
ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. Meanwhile, ANI’s $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently.
Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.
Lannett Eyes Another $11M In Savings With R&D Sea Change, Job Cuts
Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.